NCT06809595Phase 3Active not recruiting

A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)

Study sponsor: Definium Therapeutics US, Inc.

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-08-13Actual

Enrollment · participants245Actual

Source updated2026-09-04Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-09-04 · 2 fields changed

Completion date type changed

− Before

~~Estimated~~

+ After

Actual

Primary completion date changed

− Before

~~Aug 2026~~

+ After

13 Aug 2026

Check registry source

Posted 2026-06-22 · 1 field changed

Primary completion date changed

− Before

~~Nov 2026~~

+ After

Aug 2026

Check registry source

Posted 2026-05-22 · 2 fields changed

Participant count type changed

− Before

~~Estimated~~

+ After

Actual

Enrollment · participant count changed

− Before

~~250 participants (planned)~~

+ After

245 participants (actual)

Check registry source

Posted 2026-05-01 · 1 field changed

Recruitment status changed

− Before

~~Recruiting~~

+ After

Active not recruiting

Check registry source

Study details

Conditions studied

Generalized Anxiety Disorder

Treatments or interventions studied

DT120DrugAlso known as MM120, lysergide tartrate, LSD D-Tartrate

Primary outcomes · main study measures

Read the study measures

measure: Change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) total score at Week 12; description: The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.; timeFrame: Baseline to Week 12

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history